Bio-Techne (TECH)

NASDAQHealth CareBiotechnologySnapshot 2026-10-15

$72.57+0.07%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Bio-Techne’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+1.6%

+10% or more+5%0%−5%−10% or less

2.34 → 2.38 EPS · FY ending Jun 30, 2028 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain quarterly dividend of $0.08 per share	It keeps paying a steady dividend of $0.08 per share.	Intact	Dividend per share falls below $0.08	Dividend per share: $0.08 per share FY2026-Q3; GAAP. Published target: >= $0.08 per share. The target does not explicitly identify fiscal versus calendar quarters. Source published May 6, 20260.08 USD/share · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Mar 31, 2026 Source: company_financial_results. Reference: 45350b68-110a-49de-82d0-73d8aeda22df. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. Dividend per share consistently maintained at $0.08 from 2025-Q3 through 2026-Q4. Management has reiterated this capital allocation commitment with no change, indicating steady delivery on this priority. Delivery assessment Oct 15, 2026
GAAP operating margin improves to at least 24.2% by Q3 2026	Bio-Techne improves profit margins from 12.2% to 24.2% in one year.	Intact	Operating margin falls below 15% in 2026-Q3	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 of last 8 quarters. Adjusted operating margin remained stable around 32%, with adjusted operating income increasing slightly from $383.6M in 2025 to $386.1M in 2026. Management consistently cites profitability initiatives as a driver, indicating ongoing focus with limited but positive progress. Delivery assessment Oct 15, 2026
Maintain revenue near $311 million in Q3 2026	Revenue is stable near $311 million despite market challenges.	Intact	Revenue falls below $295 million in 2026-Q3	Revenue: $321.192M FY2026-Q4; GAAP. Published target: >= $311 million. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Source published Aug 24, 2026321,192,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. The divestiture was announced in 2025-Q4 and completed by 2026-Q1. Diagnostics and Spatial Biology segment operating margin improved from 6.2% in 2025 to 11.2% in 2026, reflecting delivery on profitability and strategic focus from the divestiture. Delivery assessment Oct 15, 2026
Smooth integration of Merck KGaA acquisition	The acquisition by Merck KGaA boosts growth and market position.	Intact	Material integration problems or loss of key customers reported	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS$2.38

Unavailable → $2.38 · observed estimates

FY2028 revenue$1.40B

$1.38B → $1.40B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$1,382,965,993	3 / 9
2026-07-25	Unavailable	$1,382,965,993	3 / 9
2026-07-26	Unavailable	$1,382,965,993	3 / 9
2026-07-27	Unavailable	$1,382,965,993	3 / 9
2026-07-28	Unavailable	$1,382,965,993	3 / 9
2026-07-29	Unavailable	$1,382,965,993	3 / 9
2026-07-30	Unavailable	$1,382,965,993	3 / 10
2026-07-31	Unavailable	$1,382,965,993	3 / 10
2026-08-01	Unavailable	$1,382,965,993	3 / 10
2026-08-02	Unavailable	$1,386,148,378	3 / 9
2026-08-03	Unavailable	$1,386,148,378	3 / 9
2026-08-04	Unavailable	$1,386,148,378	3 / 10
2026-08-05	Unavailable	$1,386,148,378	3 / 10
2026-08-06	Unavailable	$1,386,148,378	3 / 10
2026-08-08	Unavailable	$1,386,148,378	3 / 10
2026-08-09	Unavailable	$1,386,148,378	3 / 10
2026-08-10	Unavailable	$1,386,148,378	3 / 10
2026-08-12	Unavailable	$1,386,148,378	3 / 10
2026-08-13	Unavailable	$1,386,148,378	3 / 10
2026-08-14	Unavailable	$1,386,148,378	3 / 10
2026-08-15	Unavailable	$1,386,148,378	3 / 10
2026-08-16	Unavailable	$1,386,148,378	3 / 10
2026-08-17	Unavailable	$1,386,148,378	3 / 10
2026-08-18	Unavailable	$1,386,148,378	3 / 10
2026-08-19	Unavailable	$1,386,148,378	3 / 10
2026-08-20	Unavailable	$1,380,131,740	3 / 6
2026-08-21	Unavailable	$1,380,131,740	3 / 6
2026-08-22	Unavailable	$1,380,131,740	3 / 6
2026-08-23	Unavailable	$1,380,131,740	3 / 6
2026-08-24	Unavailable	$1,380,131,740	3 / 6
2026-08-25	Unavailable	$1,380,131,740	3 / 6
2026-08-26	Unavailable	$1,380,131,740	3 / 6
2026-08-27	Unavailable	$1,380,131,740	3 / 6
2026-08-28	Unavailable	$1,380,131,740	3 / 6
2026-08-29	Unavailable	$1,390,868,100	3 / 6
2026-08-30	Unavailable	$1,390,868,100	3 / 6
2026-08-31	Unavailable	$1,390,868,100	3 / 6
2026-09-01	Unavailable	$1,390,868,100	3 / 6
2026-09-02	Unavailable	$1,390,868,100	3 / 6
2026-09-03	Unavailable	$1,390,868,100	3 / 6
2026-09-04	Unavailable	$1,390,868,100	3 / 6
2026-09-05	Unavailable	$1,390,868,100	3 / 6
2026-09-06	Unavailable	$1,390,868,100	3 / 6
2026-09-07	Unavailable	$1,390,868,100	3 / 6
2026-09-08	$2.34	$1,390,868,100	5 / 7
2026-09-09	$2.34	$1,390,868,100	5 / 7
2026-09-10	$2.34	$1,390,868,100	5 / 7
2026-09-11	$2.34	$1,390,868,100	5 / 7
2026-09-12	$2.34	$1,390,868,100	5 / 7
2026-09-13	$2.34	$1,390,868,100	5 / 7
2026-09-14	$2.34	$1,390,868,100	5 / 7
2026-09-15	$2.34	$1,390,868,100	5 / 7
2026-09-16	$2.34	$1,390,868,100	5 / 7
2026-09-17	$2.34	$1,390,868,100	5 / 7
2026-09-18	$2.34	$1,390,868,100	5 / 7
2026-09-19	$2.34	$1,390,868,100	5 / 7
2026-09-20	$2.34	$1,390,868,100	5 / 7
2026-09-21	$2.34	$1,390,868,100	5 / 7
2026-09-22	$2.34	$1,390,868,100	5 / 7
2026-09-23	$2.34	$1,390,868,100	5 / 7
2026-09-24	$2.34	$1,390,868,100	5 / 7
2026-09-25	$2.34	$1,390,868,100	5 / 7
2026-09-26	$2.34	$1,390,868,100	5 / 7
2026-09-27	$2.34	$1,390,868,100	5 / 7
2026-09-28	$2.34	$1,390,868,100	5 / 7
2026-09-29	$2.34	$1,390,868,100	5 / 7
2026-09-30	$2.34	$1,390,868,100	5 / 7
2026-10-01	$2.33	$1,392,935,125	5 / 7
2026-10-02	$2.33	$1,392,935,125	5 / 7
2026-10-03	$2.36	$1,392,935,125	5 / 7
2026-10-04	$2.36	$1,392,935,125	5 / 7
2026-10-05	$2.35	$1,390,426,714	5 / 7
2026-10-06	$2.35	$1,390,426,714	5 / 7
2026-10-07	$2.35	$1,390,426,714	5 / 7
2026-10-08	$2.38	$1,397,414,500	5 / 7
2026-10-09	$2.38	$1,397,414,500	5 / 7
2026-10-10	$2.38	$1,397,414,500	5 / 7
2026-10-11	$2.38	$1,397,414,500	5 / 7
2026-10-12	$2.38	$1,397,414,500	5 / 7
2026-10-13	$2.38	$1,397,414,500	5 / 7
2026-10-14	$2.38	$1,397,414,500	5 / 7
2026-10-15	$2.38	$1,397,414,500	5 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	4
2026-06-01	11	11
2026-07-01	4	13
2026-08-01	2	13
2026-09-01	1	13
2026-10-01	1	12

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 12 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain quarterly dividend of $0.08 per shareDividend per share: $0.08 per share
GAAP operating margin improves to at least 24.2% by Q3 2026Direct metric needs a verified mapping
Maintain revenue near $311 million in Q3 2026Revenue: $321.192M
Smooth integration of Merck KGaA acquisitionQualitative condition

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.1%Typical daily move · historical

Downside history

-39.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Bio-Techne outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on revenue growth and profitability. The current thesis state is intact, as recent performance has been strong, but there are underlying risks that could impact future results.

What's priced into Bio-Techne

The valuation is considered expensive compared to peers, with the market pricing in a premium. There is an expectations gap of 0.23, indicating that some positive performance is already anticipated by investors.

What the fundamentals likely do

Fundamentals are likely to show mixed results. While management has prioritized revenue growth and maintained a stable dividend, recent quarterly organic revenue growth has been fluctuating, suggesting potential challenges ahead.

What Bio-Techne hinges on

The thesis hinges on several factors, including the potential for guidance cuts, the impact of economic indicators like job reports, and the performance of sector bellwethers. Positive momentum in the Healthcare sector could support TECH's growth.